Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) is the most common malignant primary brain tumor. It still carries a grim prognosis and new therapies are needed. This review summarizes the current status of mechanistic insights into the function of extracellular regulated kinase (ERK) and its potential as a therapeutic target for patients with GBM. Currently, some promising ERK inhibitors are in clinical trials in tumor entities other than GBM. Here, we provide a comprehensive overview on the functions of ERK1/2 in GBM and a rationale for treatment of GBM with ERK inhibitors.
No takes yet. Share an insight, caveat, or question.
Hannen et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: